Wedbush Has Positive Outlook for DAWN FY2028 Earnings

Key Points

• Wedbush raised its FY2028 earnings per share (EPS) estimate for Day One Biopharmaceuticals from $0.47 to $0.56, while maintaining an "Outperform" rating and a $25.00 price target.
• Day One Biopharmaceuticals recently reported a quarterly EPS of ($0.29), exceeding the consensus estimate of ($0.35) and showing revenue of $33.91 million.
• Institutional investors and hedge funds own 87.95% of Day One Biopharmaceuticals' stock, highlighting strong institutional interest in the company.

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) - Analysts at Wedbush lifted their FY2028 EPS estimates for shares of Day One Biopharmaceuticals in a report released on Tuesday, August 5th. Wedbush analyst R. Driscoll now expects that the company will post earnings per share of $0.56 for the year, up from their prior estimate of $0.47. Wedbush currently has a "Outperform" rating and a $25.00 target price on the stock. The consensus estimate for Day One Biopharmaceuticals' current full-year earnings is ($0.72) per share. Wedbush also issued estimates for Day One Biopharmaceuticals' FY2029 earnings at $1.53 EPS.

A number of other brokerages have also issued reports on DAWN. HC Wainwright decreased their target price on shares of Day One Biopharmaceuticals from $36.00 to $25.00 and set a "buy" rating on the stock in a research report on Wednesday, August 6th. Needham & Company LLC dropped their price target on Day One Biopharmaceuticals from $18.00 to $16.00 and set a "buy" rating for the company in a research note on Wednesday, August 6th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $25.33.

Day One Biopharmaceuticals Stock Performance

DAWN traded down $0.14 on Thursday, hitting $5.97. 958,547 shares of the company were exchanged, compared to its average volume of 1,364,994. The business's fifty day moving average is $6.70 and its 200 day moving average is $7.99. Day One Biopharmaceuticals has a fifty-two week low of $5.64 and a fifty-two week high of $16.76. The firm has a market capitalization of $611.01 million, a P/E ratio of -6.27 and a beta of -1.26.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported ($0.29) EPS for the quarter, beating analysts' consensus estimates of ($0.35) by $0.06. Day One Biopharmaceuticals had a negative net margin of 50.63% and a negative return on equity of 19.01%. The business had revenue of $33.91 million during the quarter, compared to analysts' expectations of $35.55 million.

Insider Activity at Day One Biopharmaceuticals

In related news, CFO Charles N. York II sold 4,282 shares of the firm's stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of $6.26, for a total value of $26,805.32. Following the sale, the chief financial officer owned 265,231 shares of the company's stock, valued at approximately $1,660,346.06. This trade represents a 1.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Jeremy Bender sold 13,964 shares of the company's stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $6.26, for a total transaction of $87,414.64. Following the completion of the transaction, the chief executive officer owned 145,737 shares of the company's stock, valued at approximately $912,313.62. This trade represents a 8.74% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 26,725 shares of company stock valued at $167,299 in the last quarter. Insiders own 6.20% of the company's stock.

Institutional Trading of Day One Biopharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of DAWN. FMR LLC boosted its position in shares of Day One Biopharmaceuticals by 73.9% in the fourth quarter. FMR LLC now owns 12,887,467 shares of the company's stock worth $163,284,000 after buying an additional 5,475,087 shares during the period. Vanguard Group Inc. boosted its stake in shares of Day One Biopharmaceuticals by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 5,943,243 shares of the company's stock valued at $47,130,000 after buying an additional 94,320 shares during the period. Alyeska Investment Group L.P. boosted its stake in shares of Day One Biopharmaceuticals by 61.6% during the 1st quarter. Alyeska Investment Group L.P. now owns 4,059,764 shares of the company's stock valued at $32,194,000 after buying an additional 1,547,577 shares during the period. Estuary Capital Management LP boosted its stake in shares of Day One Biopharmaceuticals by 35.5% during the 4th quarter. Estuary Capital Management LP now owns 3,716,777 shares of the company's stock valued at $47,092,000 after buying an additional 972,997 shares during the period. Finally, Vestal Point Capital LP boosted its stake in shares of Day One Biopharmaceuticals by 80.4% during the 1st quarter. Vestal Point Capital LP now owns 2,598,127 shares of the company's stock valued at $20,603,000 after buying an additional 1,158,127 shares during the period. Institutional investors and hedge funds own 87.95% of the company's stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.